Research Archive — Page 56 of 137

September 13, 2022

Patients had ‘significant and clinically meaningful improvement’ in survival in fruquintinib clinical trial

Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.

September 13, 2022

Cancer registries and sarcoma research

The number of sarcoma research studies that use the two largest U.S. cancer registries is increasing, but over one-third of studies that asked the same research question reported conflicting findings.

September 12, 2022

Enhancing innate immunity in the lung

Vanderbilt researchers show that a TLR4 agonist improves lung immune response and survival in a mouse model of bacterial pneumonia, supporting the development of this drug to protect against pneumonia in hospitalized patients.

September 8, 2022

PheWAS reveals post-COVID-19 diagnoses

Using a high-throughput informatics technique and electronic health records, Vanderbilt researchers found that COVID-19 survivors had an increased risk for more than 40 new diagnoses.

September 8, 2022

Immune cells drive beta cell loss in Type 2 diabetes

Vanderbilt researchers have discovered details of pancreatic beta cell loss — and potential therapeutic targets — during conditions of overnutrition, as occurs in obesity.

Luc Van Kaer, PhD, left, Luke Postoak and colleagues have identified a protein that is key to the “education” of immature T cells in the thymus.
September 1, 2022

Study identifies key player in T cell “education”

New Vanderbilt research could inform therapeutic strategies for enhancing thymic function when desired — such as during aging, recovery from radiation therapy or chemotherapy, or other conditions that reduce T cell output.